

# 45 - References

## References

### Bipolar disorder CHAPTER 2 References

1. Keramatian K, et al. Long-acting injectable second-generation/atypical antipsychotics for the management of bipolar disorder: a systematic review. *CNS Drugs* 2019; 33:431–456.
2. Pacchiarotti I, et al. Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: a systematic review. *Eur Neuropsychopharmacol* 2019; 29:457–470.
3. Prajapati AR, et al. Second-generation antipsychotic long-acting injections in bipolar disorder: systematic review and meta-analysis. *Bipolar Disord* 2018; 20:687–696.
4. Goto J, et al. Preventive effect of aripiprazole once monthly on rehospitalization for bipolar disorder: a multicenter 1-year retrospective mirror image study. *Neuropsychopharmacol Rep* 2023; 43:425–433.
5. Woo YS, et al. Preventive effect of aripiprazole once-monthly on relapse into mood episodes in bipolar disorder: a multicenter, one-year, retrospective, mirror image study. *J Affect Disord* 2024; 351:381–386.
6. Yildizhan E, et al. Effect of long acting injectable antipsychotics on course and hospitalizations in bipolar disorder – a naturalistic mirror image study. *Nord J Psychiatry* 2022; 76:37–43.
7. Caliskan AM, et al. Impact of initiating long-acting injectable paliperidone palmitate on relapse and hospitalization in patients with bipolar I disorder: a mirror image retrospective study. *Asian J Psychiatr* 2020; 54:102457.
8. Harlin M, et al. A randomized, open-label, multiple-dose, parallel-arm, pivotal study to evaluate the safety, tolerability, and pharmacokinetics of aripiprazole 2-month long-acting injectable in adults with schizophrenia or bipolar I disorder. *CNS Drugs* 2023; 37:337–350.
9. McIntyre RS, et al. Safety and efficacy of aripiprazole 2-month ready-to-use 960 mg: secondary analysis of outcomes in adult patients with bipolar I disorder in a randomized, open-label, parallel-arm, pivotal study. *Curr Med Res Opin* 2023; 39:1021–1030.
10. Esparon J, et al. Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-depressive patients. *Br J Psychiatry* 1986; 148:723–725.
11. Yatham L, et al. Randomised trial of oral vs. injectable antipsychotics in bipolar disorder. Presented at the 6th International Conference on Bipolar Disorder: 16–18 June 2005, Pittsburgh, PA.
12. Ahlfors UG, et al. Flupenthixol decanoate in recurrent manic-depressive illness. A comparison with lithium. *Acta Psychiatr Scand* 1981; 64:226–237.

13. Macfadden W, et al. A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. *Bipolar Disord* 2009; 11:827-839.
14. Quiroz JA, et al. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. *Biol Psychiatry* 2010; 68:156-162.
15. Vieta E, et al. A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder. *Eur Neuropsychopharmacol* 2012; 22:825-835.
16. Calabrese JR, et al. Efficacy and safety of aripiprazole once-monthly in the maintenance treatment of bipolar I disorder: a double-blind, placebo-controlled, 52-week randomized withdrawal study. *J Clin Psychiatry* 2017; 78:324-331.
17. Calabrese JR, et al. Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study. *Int J Bipolar Disord* 2018; 6:14.
18. Berwaerts J, et al. A randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode. *J Affect Disord* 2012; 138:247-258.
19. Buoli M, et al. Paliperidone palmitate depot in the long-term treatment of psychotic bipolar disorder: a case series. *Clin Neuropharmacol* 2015; 38:209-211.
20. Li K, et al. Case report: paliperidone palmitate in the management of bipolar I disorder with non-compliance. *Front Psychiatry* 2020; 11:529672.
21. Bond DJ, et al. Depot antipsychotic medications in bipolar disorder: a review of the literature. *Acta Psychiatr Scand Suppl* 2007; 2007:3-16.
22. Gigante AD, et al. Long-acting injectable antipsychotics for the maintenance treatment of bipolar disorder. *CNS Drugs* 2012; 26:403-420.
23. Goikolea JM, et al. Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol. *J Affect Disord* 2013; 144:191-198.
24. Wu CS, et al. Comparative effectiveness of long-acting injectable risperidone vs. long-acting injectable first-generation antipsychotics in bipolar disorder. *J Affect Disord* 2016; 197:189-195.
25. Bartoli F, et al. Effect of long-acting injectable antipsychotics on 1-year hospitalization in bipolar disorder: a mirror-image study. *Eur Arch Psychiatry Clin Neurosci* 2023; 273:1579--1586.

---

Revision #1

Created 2026-01-04 20:14:28 UTC by Omar Ayman

Updated 2026-01-04 20:14:28 UTC by Omar Ayman